Acadia Pharma (ACAD) Misses Q1 EPS by 7c, Revs Beat

Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.59), $0.07 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $62.96 million versus the consensus estimate of $60.69 million.

GUIDANCE:

Acadia Pharma sees FY2019 revenue of $280-300 million, versus the consensus of $291.2 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance